Reaction
Product Confusion reporting signals
As of the last recalculation, Product Confusion appears in 767 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE (PRR 174.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 198 | 174.5 | 175.3 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 47 | 81.3 | 81.5 |
| Fluticasone Furoate And Vilanterol Trifenatate | 79 | 66.3 | 66.5 |
| Umeclidinium | 19 | 59.0 | 59.1 |
| Fluticasone Furoate | 11 | 25.0 | 25.0 |
| Fluticasone Propionate And Salmeterol | 24 | 16.1 | 16.1 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 6 | 15.7 | 15.7 |
| Oral Semaglutide | 38 | 14.7 | 14.7 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 8 | 12.1 | 12.1 |
| Nirmatrelvir And Ritonavir | 14 | 7.1 | 7.1 |